PHILADELPHIA, PA & SAN FRANCISCO, CA & SHANGHAI, China — Dispatch Bio and CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) said they have entered into a clinical collaboration to conduct a Phase 1 trial in China evaluating an investigational therapy for solid tumors, with the study expected to begin in 2026.
The planned trial will assess DISP-11, a combination therapy built on Dispatch’s Flare platform, which includes DV-10, a tumor-specific virus designed to modify the tumor environment and enable CAR T-cell targeting. The study will pair DV-10 with CARsgen’s zevorcabtagene autoleucel, or zevor-cel, an autologous B-cell maturation antigen-targeting CAR T-cell therapy.
Zevor-cel is approved by China’s National Medical Products Administration for the treatment of multiple myeloma, making it one of the commercially validated CAR T therapies in the Chinese market.
Under the trial design, patients with solid tumors of epithelial origin will first receive DV-10, followed by treatment with zevor-cel. Epithelial tumors account for roughly 90 percent of all solid tumors, a category that has historically been resistant to CAR T-cell approaches.
CARsgen said the collaboration aligns with its strategy to expand the application of CAR T technologies beyond blood cancers. Company founder and chief executive Zonghai Li said the Flare platform offers a complementary approach for addressing solid tumors that lack clear molecular targets.
Dispatch said the partnership represents a strategic step in expanding the global reach of its Flare platform, particularly in regions with established oncology development infrastructure. Chief executive Sabah Oney said CARsgen’s experience in advancing and commercializing CAR T therapies in China positions the collaboration to generate early clinical insights that could inform broader development efforts.
The companies said the study marks Dispatch’s second collaboration with a partner that has successfully commercialized a CAR T therapy, reflecting growing interest in the Flare platform’s potential role in next-generation immuno-oncology strategies.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.